Literature DB >> 4384530

Antigen-induced release of slow reacting substance of anaphylaxis (SRS-A rat) in rats prepared with homologous antibody.

R P Orange, M D Valentine, K F Austen.   

Abstract

The polymorphonuclear leukocyte appears to be an essential cellular prerequisite for the antigen-induced release of SRS-A(rat) in the peritoneal cavity of rats prepared with homologous, hyperimmune antisera. Depletion of PMN leukocytes is associated with a marked suppression of SRS-A(rat) release, whereas depletion of circulating lymphocytes or peritoneal mast cells does not influence the antigen-induced release of SRS-A(rat). A local increase in the number of PMN leukocytes produced by the induction of a peritoneal exudate was associated with an enhanced release of SRS-A(rat). A distinct difference in the cellular requirements for the antigen-induced release of histamine and SRS-A(rat) in the rat was observed. Homocytotropic antibody-mediated histamine release could be achieved in leukopenic rats but not in mast cell-depleted animals. Conversely, SRS-A(rat) release was suppressed in leukopenic rats but was unaffected by mast cell depletion. Diethylcarbamazine inhibited the antigen-induced release of SRS-A(rat) following preparation with homologous, hyperimmune antisera but did not interfere with homocytotropic antibody-mediated histamine release. In preventing SRS-A(rat) release, diethylcarbamazine did not interfere with antigen-antibody interaction since desensitization of tissues was possible in the presence of this inhibitor. This observation is consistent with the view that diethylcarbamazine inhibits the reaction sequence leading to the formation and release of SRS-A(rat) at some step subsequent to antigen-antibody interaction. These studies support the view that the immunologic pathways leading to the release of SRS-A(rat) and histamine in the rat are distinctly different in terms of the immunoglobulins involved, the cellular prerequisites, and the effective pharmacologic inhibitors.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4384530      PMCID: PMC2138477          DOI: 10.1084/jem.127.4.767

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  17 in total

1.  THE MECHANISM OF ANAPHYLAXIS. I. PRODUCTION AND BIOLOGICAL PROPERTIES OF 'MAST CELL SENSITIZING' ANTIBODY.

Authors:  I MOTA
Journal:  Immunology       Date:  1964-11       Impact factor: 7.397

2.  Isolation of "biologically intact" mast cells.

Authors:  B UVNAS; I L THON
Journal:  Exp Cell Res       Date:  1959-11       Impact factor: 3.905

3.  The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock.

Authors:  W E BROCKLEHURST
Journal:  J Physiol       Date:  1960-06       Impact factor: 5.182

4.  Liberation of histamine and formation of lysocithin-like substances by cobra venom.

Authors:  W Feldberg; C H Kellaway
Journal:  J Physiol       Date:  1938-11-14       Impact factor: 5.182

5.  Failure of rat and rabbit antiserum to passively sensitize normal and pertussis-treated rats and mice so as to induce mast cell damage and histamine release on later contact with antigen.

Authors:  I MOTA
Journal:  Immunology       Date:  1962-01       Impact factor: 7.397

6.  Further studies on the chemotactic factor of complement and its formation in vivo.

Authors:  P A Ward; C G Cochrane; H J Muller-Eberhard
Journal:  Immunology       Date:  1966-08       Impact factor: 7.397

7.  Mechanisms of immunologic injury of rat peritoneal mast cells. 3. Cytotoxic histamine release.

Authors:  M D Valentine; K J Bloch; K F Austen
Journal:  J Immunol       Date:  1967-07       Impact factor: 5.422

8.  Production of antibody against bradykinin: demonstration of specificity by complement fixation and radio-immunoassay.

Authors:  J Spragg; K F Austen; E Haber
Journal:  J Immunol       Date:  1966-05       Impact factor: 5.422

9.  Mechanisms of immunologic injury of rat peritoneal mast cells. I. The effect of phosphonate inhibitors on the homocytotropic antibody-mediated histamine release and the first component of rat complement.

Authors:  E L Becker; K F Austen
Journal:  J Exp Med       Date:  1966-09-01       Impact factor: 14.307

10.  Immunological specificity of delayed and immediate hypersensitivity reactions.

Authors:  B BENACERRAF; B B LEVINE
Journal:  J Exp Med       Date:  1962-05-01       Impact factor: 14.307

View more
  18 in total

Review 1.  Mast cells and mastocytosis.

Authors:  Dean D Metcalfe
Journal:  Blood       Date:  2008-08-15       Impact factor: 22.113

2.  Isolation of human eosinophil phospholipase D.

Authors:  L A Kater; E J Goetzl; K F Austen
Journal:  J Clin Invest       Date:  1976-05       Impact factor: 14.808

3.  Arylsulfatase B of human lung. Isolation, characterization, and interaction with slow-reacting substance of anaphylaxis.

Authors:  S I Wasserman; K F Austen
Journal:  J Clin Invest       Date:  1976-03       Impact factor: 14.808

4.  The contractile action of slow reacting substance of anaphylaxis (SRS-A) on guinea-pig isolated lung strip [proceedings].

Authors:  R A Coleman; I Kennedy; C J Whelan
Journal:  Br J Pharmacol       Date:  1979-05       Impact factor: 8.739

5.  Immunological and pharmacological analysis of the primary and secondary reagin response to Nippostrongylus brasiliensis in the rat.

Authors:  R Keller; V E Jones
Journal:  Immunology       Date:  1971-10       Impact factor: 7.397

6.  On the preparation of highly purified slow reacting substance of anaphylaxis (SRS-A) from biological extracts [proceedings].

Authors:  G L Blackwell; J F Burka; R J Flower
Journal:  Br J Pharmacol       Date:  1978-06       Impact factor: 8.739

Review 7.  Role of lymphokines in immediate type allergy.

Authors:  B M Stadler; A L de Weck
Journal:  Springer Semin Immunopathol       Date:  1984

8.  On the preparation of highly purified slow reacting substance of anaphylaxis (SRS-A) from biological extracts.

Authors:  G J Blackwell; J F Burka; R J Flower; P Torkington
Journal:  Br J Pharmacol       Date:  1980-01       Impact factor: 8.739

9.  Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue.

Authors:  R Huey; C M Bloor; M S Kawahara; T E Hugli
Journal:  Am J Pathol       Date:  1983-07       Impact factor: 4.307

10.  Effects of modulators of arachidonic acid metabolism on the synthesis and release of slow-reacting substance of anaphylaxis.

Authors:  J F Burka; R J Flower
Journal:  Br J Pharmacol       Date:  1979-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.